Posted by Michael Wonder on 16 Mar 2022
Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active ulcerative colitis
16 March 2022 - In clinical trials, Rinvoq (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score) at weeks 8 and 52.
AbbVie today announced that the U.S. FDA has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumour necrosis factor blockers.
